(accessed 24 August 2020).12 12. Children's Oncology Group: Long‐term follow‐up guidelines for survivors of childhood, adolescent, and young adult cancers. 2018. Available from: http://www.survivorshipguidelines.org/ ().
13 13. Chow EJ, Anderson L, Baker KS, et al. Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: A children's oncology group report. Biol Blood Marrow Transplant. 2016; 22(5):782–795.
14 14. International Guideline Harmonization Group for Late Effects of Childhood Cancer. Available from: https://www.ighg.org/international‐guideline‐harmonization‐group/ (accessed 24 August 2020).
15 15. Shenoy S, Gaziev J, Angelucci E, al. Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: Consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2018; 24(7):1313–1321.
16 16. Heimall J, Buckley RH, Puck J, et al. Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017; 23(8):1229–1240.
17 17. Dietz AC, Savage SA, Vlachos A, et al. Late effects screening guidelines after hematopoietic cell transplantation for inherited bone marrow failure syndromes: Consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Biol Blood Marrow Transplant. 2017; 23(9):1422–1428.
18 18. Hartz B, Marsh R, Rao K, et al. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood. 2016; 127(25):3281–3290.
19 19. Rose C, Ernst O, Hecquet B, et al. Quantification by magnetic resonance imaging and liver consequences of post‐transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica. 2007; 92(6):850–853.
20 20. Altes A, Remacha AF, Sarda P, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 2004; 34(6):505–509.
21 21. Lucarelli G, Angelucci E, Giardini C, et al. Fate of iron stores in thalassemia after bone marrow transplantation. Lancet. 1993; 342:1388–1391.
22 22. Trottier BJ, Burns LJ, Defor TE, et al. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2‐MRI‐measured liver iron content. Blood. 2013; 122:1678–1684.
23 23. St Pierre TG, Clark PR, Chua‐anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005; 105(2):855–861.
24 24. Majhail NS, DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2008; 14(7):790–794.
25 25. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood. 1997; 90(3):994–998.
26 26. Mariotti E, Angelucci E, Agostini A, et al. Evaluation of cardiac status in iron‐loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol. 1998; 103(4):916–921.
27 27. Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft‐versus‐host disease: A task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2017; 23(2):211–234.
28 28. Baird K, Cooke K, Schultz KR. Chronic graft‐versus‐host disease (GVHD) in children. Pediatr Clin North Am. 2010; 57(1):297–322.
29 29. Zecca M, Prete A, Rondelli R, et al. Chronic graft‐versus‐host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002; 100(4):1192–1200.
30 30. Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft‐versus‐host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22(3):449–455.
31 31. Cuvelier GDE, Nemecek ER, Wahlstrom JT, et al. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood. 2019; 134(3):304–316.
32 32. Norkin M, Shaw BE, Brazauskas R, et al. Characteristics oflate fatal infections after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(2):362–368.
33 33. Inamoto Y, Storer BE, Petersdorf EW, et al. Incidence, risk factors and outcomes of sclerosis in patients with chronic graft‐versus‐host disease. Blood. 2013; 121(25):5098–5103.
34 34. Inamoto Y, Pidala J, Chai X, et al. Assessment of joint and fascia manifestations in chronic graft‐versus‐host disease. Arthritis and Rheumatology. 2014; 66(4):1044–1052.
35 35. Inamoto Y, Lee SJ, Onstad LE, et al. Refined National Institutes of Health response algorithm for chronic graft‐versus‐host disease in joints and fascia. Blood Adv. 2020; 4(1):40–46.
36 36. Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft‐versus‐Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015; 21(7):1167–1187.
37 37. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3):e44–100.
38 38. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016; 127(23):2824–2832.
39 39. Five things physicians and patients should question. Choosing Wisely ‐ An initiative of the ABIM Foundation. Available from: https://www.choosingwisely.org/wp‐content/uploads/2018/01/ASTCT‐CTTC‐Choosing‐Wisely‐List_2019.pdf (accessed 24 August 2020).
40 40. Suh DW, Ruttum MS, Stuckenschneider BJ, et al. Ocular findings after bone marrow transplantation in a pediatric population. Ophthalmology. 1999; 106(8):1564–1570.
41 41. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft‐versus‐host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015; 21(6):984–999.
42 42. Galbán CJ, Boes JL, Bule M, et al. Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(10):1592–1598.
43 43. Bergeron A, Chevret S, Chagnon K, et al. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation.
